Value of the Definition of Severe Familial Hypercholesterolemia for Stratification of Heterozygous Patients
Abstract Familial hypercholesterolemia (FH) is characterized by high low-density lipoprotein (LDL) cholesterol with co-dominant transmission and high risk of cardiovascular disease (CVD), although with high variability among subjects. Currently, CVD stratification tools for heterozygous FH (HeFH) ar...
Saved in:
Published in: | The American journal of cardiology Vol. 119; no. 5; pp. 742 - 748 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
Elsevier Inc
01-03-2017
Elsevier Limited |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Abstract Familial hypercholesterolemia (FH) is characterized by high low-density lipoprotein (LDL) cholesterol with co-dominant transmission and high risk of cardiovascular disease (CVD), although with high variability among subjects. Currently, CVD stratification tools for heterozygous FH (HeFH) are not available. A definition of severe HeFH has been recently proposed by the International Atherosclerosis Society (IAS), but it has not been validated. Our study aims to see clinical characteristics and prevalence of CVD in subjects defined as severe HeFH by IAS criteria. Probable or definite HeFH introduced in the Dyslipidemia Registry of Spanish Arteriosclerosis Society were analyzed by the IAS criteria. Univariate and multivariate analysis was used to assess the association of CVD with the IAS criteria. 1,732 HeFH cases were analysed. Severe HeFH had higher prevalence of: familial history of CVD, personal history of tendon xanthomas, LDL cholesterol and CVD than those non-severe HeFH. A total of 656 (77.1%) and 441 (50.1%) of men and women, respectively, fulfilled the IAS criteria of severe HeFH. In the univariate analysis, subjects defined as severe HeFH showed OR 3.016 (95% CI 3.136-4.257, p<0.001) for CVD. However, when traditional risk factors were included in the multivariate analysis only the presence of LDL cholesterol >400 mg/dl had a statistically significant association with CVD OR 8.76 (95% CI 3.90-19.69, p<0.001). In conclusion, the IAS definition of severe HeFH is not significantly associated with CVD when adjusted for classic risk factors. Risk stratification in HeFH is an important issue but the proposed criteria do not seem to solve this problem. |
---|---|
AbstractList | Familial hypercholesterolemia (FH) is characterized by high low-density lipoprotein (LDL) cholesterol with co-dominant transmission and high risk of cardiovascular disease (CVD), although with high variability among subjects. Currently, CVD stratification tools for heterozygous FH (HeFH) are not available. A definition of severe HeFH has been recently proposed by the International Atherosclerosis Society (IAS), but it has not been validated. Our study aims to see clinical characteristics and prevalence of CVD in subjects defined as severe HeFH by IAS criteria. Probable or definite HeFH introduced in the Dyslipidemia Registry of Spanish Arteriosclerosis Society were analyzed by the IAS criteria. Univariate and multivariate analysis was used to assess the association of CVD with the IAS criteria. About 1,732 HeFH cases were analyzed. Severe HeFH had higher prevalence of familial history of CVD, personal history of tendon xanthomas, LDL cholesterol, and CVD than nonsevere HeFH. A total of 656 (77.1%) and 441 (50.1%) of men and women, respectively, fulfilled the IAS criteria of severe HeFH. In the univariate analysis, subjects defined as severe HeFH showed odds ratio 3.016 (95% CI 3.136 to 4.257, p <0.001) for CVD. However, when traditional risk factors were included in the multivariate analysis, only the presence of cholesterol >400 mg/dl had a statistically significant association with CVD odds ratio 8.76 (95% CI 3.90 to 19.69, p <0.001). In conclusion, the IAS definition of severe HeFH is not significantly associated with CVD when adjusted for classic risk factors. Risk stratification in HeFH is an important issue, but the proposed criteria do not seem to solve this problem. Abstract Familial hypercholesterolemia (FH) is characterized by high low-density lipoprotein (LDL) cholesterol with co-dominant transmission and high risk of cardiovascular disease (CVD), although with high variability among subjects. Currently, CVD stratification tools for heterozygous FH (HeFH) are not available. A definition of severe HeFH has been recently proposed by the International Atherosclerosis Society (IAS), but it has not been validated. Our study aims to see clinical characteristics and prevalence of CVD in subjects defined as severe HeFH by IAS criteria. Probable or definite HeFH introduced in the Dyslipidemia Registry of Spanish Arteriosclerosis Society were analyzed by the IAS criteria. Univariate and multivariate analysis was used to assess the association of CVD with the IAS criteria. 1,732 HeFH cases were analysed. Severe HeFH had higher prevalence of: familial history of CVD, personal history of tendon xanthomas, LDL cholesterol and CVD than those non-severe HeFH. A total of 656 (77.1%) and 441 (50.1%) of men and women, respectively, fulfilled the IAS criteria of severe HeFH. In the univariate analysis, subjects defined as severe HeFH showed OR 3.016 (95% CI 3.136-4.257, p<0.001) for CVD. However, when traditional risk factors were included in the multivariate analysis only the presence of LDL cholesterol >400 mg/dl had a statistically significant association with CVD OR 8.76 (95% CI 3.90-19.69, p<0.001). In conclusion, the IAS definition of severe HeFH is not significantly associated with CVD when adjusted for classic risk factors. Risk stratification in HeFH is an important issue but the proposed criteria do not seem to solve this problem. Familial hypercholesterolemia (FH) is characterized by high low-density lipoprotein (LDL) cholesterol with co-dominant transmission and high risk of cardiovascular disease (CVD), although with high variability among subjects. Currently, CVD stratification tools for heterozygous FH (HeFH) are not available. A definition of severe HeFH has been recently proposed by the International Atherosclerosis Society (IAS), but it has not been validated. Our study aims to see clinical characteristics and prevalence of CVD in subjects defined as severe HeFH by IAS criteria. Probable or definite HeFH introduced in the Dyslipidemia Registry of Spanish Arteriosclerosis Society were analyzed by the IAS criteria. Univariate and multivariate analysis was used to assess the association of CVD with the IAS criteria. About 1,732 HeFH cases were analyzed. Severe HeFH had higher prevalence of familial history of CVD, personal history of tendon xanthomas, LDL cholesterol, and CVD than nonsevere HeFH. A total of 656 (77.1%) and 441 (50.1%) of men and women, respectively, fulfilled the IAS criteria of severe HeFH. In the univariate analysis, subjects defined as severe HeFH showed odds ratio 3.016 (95% CI 3.136 to 4.257, p <0.001) for CVD. However, when traditional risk factors were included in the multivariate analysis, only the presence of cholesterol >400 mg/dl had a statistically significant association with CVD odds ratio 8.76 (95% CI 3.90 to 19.69, p <0.001). In conclusion, the IAS definition of severe HeFH is not significantly associated with CVD when adjusted for classic risk factors. Risk stratification in HeFH is an important issue, but the proposed criteria do not seem to solve this problem. |
Author | Pérez-Calahorra, Sofia, RD, MSc Pedro-Botet, Juan, MD, PhD Brea, Angel, MD, PhD Ascaso, Juan Francisco, MD, PhD Marco-Benedi, Victoria, RD Sánchez-Hernández, Rosa, MD Almagro, Fatima, MD, PhD Plana, Núria, MD, PhD Civeira, Fernando, MD, PhD Lahoz, Carlos, MD, PhD |
Author_xml | – sequence: 1 fullname: Pérez-Calahorra, Sofia, RD, MSc – sequence: 2 fullname: Sánchez-Hernández, Rosa, MD – sequence: 3 fullname: Plana, Núria, MD, PhD – sequence: 4 fullname: Marco-Benedi, Victoria, RD – sequence: 5 fullname: Pedro-Botet, Juan, MD, PhD – sequence: 6 fullname: Almagro, Fatima, MD, PhD – sequence: 7 fullname: Brea, Angel, MD, PhD – sequence: 8 fullname: Ascaso, Juan Francisco, MD, PhD – sequence: 9 fullname: Lahoz, Carlos, MD, PhD – sequence: 10 fullname: Civeira, Fernando, MD, PhD |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28081939$$D View this record in MEDLINE/PubMed |
BookMark | eNqFUcFu1DAQtVAR3RY-ARSJc4LHTpz4AkKlZZEqFWkBcbO8zpg6TeLFTiptv76OdgsSF06jGb33Zt6bM3Iy-hEJeQ20AAriXVfooTM6tAVLbQFQUFY9IytoapmDBH5CVpRSlkso5Sk5i7FLLUAlXpBT1tAGJJcrcvdD9zNm3mbTLWaf0LrRTc6Py2SD9xgwu9KD653us_V-h8Hc-h7jhCGVwenM-pBtpqAnZ53RT9Q1LoiH_S8_x-xrGuM4xZfkudV9xFfHek6-X11-u1jn1zefv1x8vM5N2cCUV2WFZdVKKxFYazU2Jl3NytpqwxpLeS3NVgDXQhhW2ZJZXleW0YZTI7jY8nPy9qC7C_73nI5VnZ_DmFYqaISUZS0qmlDVAWWCjzGgVbvgBh32CqhaIladOkaslogVgEoRJ96bo_q8HbD9w3rKNAE-HACYPN47DCqa5N9g6wKaSbXe_XfF-38UTJ_-YnR_h3uMf92oyBRVm-XPy5tBcGhk-ZM_ArRBpxQ |
CODEN | AJCDAG |
CitedBy_id | crossref_primary_10_1016_j_arcmed_2019_12_017 crossref_primary_10_1093_eurheartj_ehae417 crossref_primary_10_1016_j_atherosclerosis_2018_12_013 crossref_primary_10_1097_MOL_0000000000000519 crossref_primary_10_5551_jat_RV17063 crossref_primary_10_1038_s41598_023_47147_z crossref_primary_10_2478_sjecr_2019_0056 crossref_primary_10_1016_j_jacasi_2021_07_011 crossref_primary_10_1080_21678707_2017_1394841 crossref_primary_10_1016_j_jacl_2020_07_006 crossref_primary_10_1016_j_rec_2019_09_001 crossref_primary_10_1016_j_atherosclerosis_2018_11_014 crossref_primary_10_1016_j_recesp_2019_08_005 crossref_primary_10_1016_j_tcm_2020_03_004 |
Cites_doi | 10.1093/eurheartj/ehs038 10.1161/01.CIR.92.3.290 10.1016/S0021-9150(98)00200-7 10.1161/01.CIR.49.3.476 10.1056/NEJMoa1410489 10.1016/j.atherosclerosis.2016.05.037 10.1016/j.jacc.2013.11.002 10.1016/S0140-6736(14)61399-4 10.1002/humu.1380010602 10.1016/j.atherosclerosis.2013.12.020 10.1093/eurheartj/ehn422 10.1016/j.arteri.2013.07.005 10.1161/CIR.0000000000000297 10.1161/JAHA.114.001236 10.1016/j.jacl.2011.04.001 10.1016/j.jacl.2015.02.003 10.1016/j.jacc.2015.05.001 10.1093/eurheartj/eht273 10.1161/01.ATV.0000177811.14176.2b |
ContentType | Journal Article |
Copyright | Elsevier Inc. 2016 Elsevier Inc. Copyright © 2016 Elsevier Inc. All rights reserved. Copyright Elsevier Limited Mar 1, 2017 |
Copyright_xml | – notice: Elsevier Inc. – notice: 2016 Elsevier Inc. – notice: Copyright © 2016 Elsevier Inc. All rights reserved. – notice: Copyright Elsevier Limited Mar 1, 2017 |
CorporateAuthor | Dyslipidemia Registry of Spanish Arteriosclerosis Society |
CorporateAuthor_xml | – name: Dyslipidemia Registry of Spanish Arteriosclerosis Society |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7RV 7TS 7X7 7XB 88E 8FD 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ GUQSH K9. KB0 M0S M1P M2O M7Z MBDVC NAPCQ P64 PQEST PQQKQ PQUKI Q9U |
DOI | 10.1016/j.amjcard.2016.11.025 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Nursing & Allied Health Database Physical Education Index Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Technology Research Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Research Library Biochemistry Abstracts 1 Research Library (Corporate) Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central Basic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Research Library Prep ProQuest Central Student Technology Research Database ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College Research Library (Alumni Edition) Physical Education Index ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Research Library ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Biochemistry Abstracts 1 ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic ProQuest Central (Alumni) |
DatabaseTitleList | Research Library Prep MEDLINE |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1879-1913 |
EndPage | 748 |
ExternalDocumentID | 4315594071 10_1016_j_amjcard_2016_11_025 28081939 S000291491631894X 1_s2_0_S000291491631894X |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Spanish Ministry of Economy and Competitiveness grantid: PI12/01087; PI12/01703; PI12/01321 – fundername: Red de Investigación Cardiovascular grantid: RD12/0042/0055 |
GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 123 1B1 1CY 1P~ 1RT 1~. 1~5 23M 3O- 3V. 4.4 457 4G. 53G 5RE 5VS 6J9 7-5 71M 7RV 7X7 88E 8FI 8FJ 8G5 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIKJ AAKOC AALRI AAQFI AAQQT AAQXK AAWTL AAXKI AAXUO AAYOK ABBQC ABFNM ABJNI ABLJU ABMAC ABMZM ABOCM ABPPZ ABUWG ABXDB ACDAQ ACGFO ACGFS ACIUM ACIWK ACPRK ACRLP ADBBV ADEZE ADFRT ADMUD ADUKH AEBSH AEKER AENEX AEVXI AFCTW AFFNX AFJKZ AFKRA AFKWA AFRAH AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AHMBA AIEXJ AIKHN AITUG AJOXV AJRQY AJUYK AKRWK ALIPV ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN AZQEC BENPR BKEYQ BKOJK BKOMP BLXMC BNPGV BPHCQ BVXVI CCPQU CS3 DWQXO EBS EFJIC EJD EMOBN EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HEB HMK HMO HVGLF HZ~ IH2 IHE J1W J5H K-O KOM L7B M1P M29 M2O M41 MO0 N9A NAPCQ O-L O9- OA. OAUVE OHT OL~ OVD OZT P-8 P-9 P2P PC. PQQKQ PROAC PSQYO Q38 R2- RIG ROL RPZ SAE SDF SDG SEL SES SJN SPCBC SSH SSZ SV3 T5K TEORI TWZ UNMZH UV1 WH7 WOW WUQ X7M XPP YFH YOC YQJ YYP YZZ Z5R ZGI ZXP ~G- AAIAV ABLVK ABYKQ AJBFU EFLBG HMCUK LCYCR UKHRP ZA5 CGR CUY CVF ECM EIF NPM AAYXX CITATION 7TS 7XB 8FD 8FK FR3 K9. M7Z MBDVC P64 PQEST PQUKI Q9U |
ID | FETCH-LOGICAL-c481t-545e45d9f9e12dfae8c156247fac28f0379cb613a66c25f42f375f20830c636b3 |
ISSN | 0002-9149 |
IngestDate | Wed Nov 06 08:30:46 EST 2024 Thu Nov 21 23:45:25 EST 2024 Sat Sep 28 08:49:37 EDT 2024 Fri Feb 23 02:17:24 EST 2024 Tue Oct 15 14:37:31 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | cardiovascular disease Severe HeFH risk factors |
Language | English |
License | Copyright © 2016 Elsevier Inc. All rights reserved. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c481t-545e45d9f9e12dfae8c156247fac28f0379cb613a66c25f42f375f20830c636b3 |
PMID | 28081939 |
PQID | 1869947650 |
PQPubID | 41200 |
PageCount | 7 |
ParticipantIDs | proquest_journals_1869947650 crossref_primary_10_1016_j_amjcard_2016_11_025 pubmed_primary_28081939 elsevier_sciencedirect_doi_10_1016_j_amjcard_2016_11_025 elsevier_clinicalkeyesjournals_1_s2_0_S000291491631894X |
PublicationCentury | 2000 |
PublicationDate | 2017-03-01 |
PublicationDateYYYYMMDD | 2017-03-01 |
PublicationDate_xml | – month: 03 year: 2017 text: 2017-03-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: New York |
PublicationTitle | The American journal of cardiology |
PublicationTitleAlternate | Am J Cardiol |
PublicationYear | 2017 |
Publisher | Elsevier Inc Elsevier Limited |
Publisher_xml | – name: Elsevier Inc – name: Elsevier Limited |
References | Masana, Civeira, Pedro-Botet, de Castro, Pocoví, Plana, Mateo-Gallego, Jarauta, Pedragosa (bib14) 2013; 25 Civeira, Castillo, Alonso, Meriño-Ibarra, Cenarro, Artied, Martín-Fuentes, Ros, Pocoví, Mata (bib17) 2005; 25 Piepoli, Hoes, Agewall, Albus, Brotons, Catapano, Cooney, Corrà, Cosyns, Deaton, Graham, Hall, Hobbs, Løchen, Löllgen, Marques-Vidal, Perk, Prescott, Redon, Richter, Sattar, Smulders, Tiberi, van der Worp, van Dis, Verschuren, De Backer, Roffi, Aboyans, Bachl, Bueno, Carerj, Cho, Cox, De Sutter, Egidi, Fisher, Fitzsimons, Franco, Guenoun, Jennings, Jug, Kirchhof, Kotseva, Lip, Mach, Mancia, Bermudo, Mezzani, Niessner, Ponikowski, Rauch, Rydén, Stauder, Turc, Wiklund, Windecker, Zamorano (bib10) 2016; 252 Hobbs, Brown, Goldstein (bib2) 1992; 1 Stone, Levy, Fredrickson, Verter (bib3) 1974; 49 Raal, Stein, Dufour, Turner, Civeira, Burgess, Langslet, Scott, Olsson, Sullivan, Hovingh, Cariou, Gouni-Berthold, Somaratne, Bridges, Scott, Wasserman, Gaudet (bib20) 2015; 385 Jacobson, Ito, Maki, Orringer, Bays, Jones, McKenney, Grundy, Gill, Wild, Wilson, Brown (bib9) 2015; 9 (bib18) 1999; 142 Ito, McGowan, Moriarty (bib8) 2011; 5 Mundal, Sarancic, Ose, Iversen, Borgan, Veierød, Leren, Retterstøl (bib5) 2014; 3 Santos, Gidding, Hegele, Cuchel, Barter, Watts, Baum, Catapano, Chapman, Defesche, Folco, Freiberger, Genest, Hovingh, Harada-Shiba, Humphries, Jackson, Mata, Moriarty, Raal, Al-Rasadi, Ray, Reiner, Sijbrands, Yamashita (bib12) 2016; 4 Gidding, Champagne, de Ferranti, Defesche, Ito, Knowles, McCrindle, Raal, Rader, Santos, Lopes-Virella, Watts, Wierzbicki (bib13) 2015; 132 Neil, Cooper, Betteridge, Capps, McDowell, Durrington, Seed, Humphries (bib4) 2008; 29 Nordestgaard, Chapman, Humphries, Ginsberg, Masana, Descamps, Wiklund, Hegele, Raal, Defesche, Wiegman, Santos, Watts, Parhofer, Hovingh, Kovanen, Boileau, Averna, Borén, Bruckert, Catapano, Kuivenhoven, Pajukanta, Ray, Stalenhoef, Stroes, Taskinen, Tybjærg-Hansen (bib7) 2013; 34 Giugliano, Sabatine (bib21) 2015; 65 Goldstein, Hobbs, Brown (bib1) 2001 Huijgen, Kindt, Defesche, Kastelein (bib6) 2012; 33 Besseling, Kindt, Hof, Kastelein, Hutten, Hovingh (bib19) 2014; 233 Stone, Robinson, Lichtenstein, Bairey Merz, Blum, Eckel, Goldberg, Gordon, Levy, Lloyd-Jones, McBride, Schwartz, Shero, Smith, Watson, Wilson (bib11) 2014; 63 Ferrieres, Lambert, Lussier-Cacan, Davignon (bib16) 1995; 92 Cannon, Blazing, Giugliano, McCagg, White, Theroux, Darius, Lewis, Ophuis, Jukema, De Ferrari, Ruzyllo, De Lucca, Im, Bohula, Reist, Wiviott, Tershakovec, Musliner, Braunwald, Califf (bib15) 2015; 372 Piepoli (10.1016/j.amjcard.2016.11.025_bib10) 2016; 252 (10.1016/j.amjcard.2016.11.025_bib18) 1999; 142 Ferrieres (10.1016/j.amjcard.2016.11.025_bib16) 1995; 92 Raal (10.1016/j.amjcard.2016.11.025_bib20) 2015; 385 Stone (10.1016/j.amjcard.2016.11.025_bib3) 1974; 49 Mundal (10.1016/j.amjcard.2016.11.025_bib5) 2014; 3 Giugliano (10.1016/j.amjcard.2016.11.025_bib21) 2015; 65 Cannon (10.1016/j.amjcard.2016.11.025_bib15) 2015; 372 Goldstein (10.1016/j.amjcard.2016.11.025_bib1) 2001 Ito (10.1016/j.amjcard.2016.11.025_bib8) 2011; 5 Santos (10.1016/j.amjcard.2016.11.025_bib12) 2016; 4 Masana (10.1016/j.amjcard.2016.11.025_bib14) 2013; 25 Gidding (10.1016/j.amjcard.2016.11.025_bib13) 2015; 132 Hobbs (10.1016/j.amjcard.2016.11.025_bib2) 1992; 1 Besseling (10.1016/j.amjcard.2016.11.025_bib19) 2014; 233 Nordestgaard (10.1016/j.amjcard.2016.11.025_bib7) 2013; 34 Stone (10.1016/j.amjcard.2016.11.025_bib11) 2014; 63 Jacobson (10.1016/j.amjcard.2016.11.025_bib9) 2015; 9 Civeira (10.1016/j.amjcard.2016.11.025_bib17) 2005; 25 Huijgen (10.1016/j.amjcard.2016.11.025_bib6) 2012; 33 Neil (10.1016/j.amjcard.2016.11.025_bib4) 2008; 29 |
References_xml | – volume: 63 start-page: 2889 year: 2014 end-page: 2934 ident: bib11 article-title: 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines publication-title: J Am Coll Cardiol contributor: fullname: Wilson – volume: 92 start-page: 290 year: 1995 end-page: 295 ident: bib16 article-title: Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation publication-title: Circulation contributor: fullname: Davignon – volume: 142 start-page: 105 year: 1999 end-page: 112 ident: bib18 article-title: Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management publication-title: Atherosclerosis – volume: 49 start-page: 476 year: 1974 end-page: 488 ident: bib3 article-title: Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia publication-title: Circulation contributor: fullname: Verter – volume: 9 start-page: 129 year: 2015 end-page: 169 ident: bib9 article-title: National lipid association recommendations for patient-centered management of dyslipidemia: part 1—full report publication-title: J Clin Lipidol contributor: fullname: Brown – volume: 252 start-page: 207 year: 2016 end-page: 274 ident: bib10 article-title: 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and other societies on Cardiovascular Disease prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) publication-title: Atherosclerosis contributor: fullname: Zamorano – volume: 1 start-page: 445 year: 1992 end-page: 466 ident: bib2 article-title: Molecular genetics of the LDL receptor gene in familial hypercholesterolemia publication-title: Hum Mutat contributor: fullname: Goldstein – volume: 33 start-page: 2325 year: 2012 end-page: 2330 ident: bib6 article-title: Cardiovascular risk in relation to functionality of sequence variants in the gene coding for the low-density lipoprotein receptor: a study among 29,365 individuals tested for 64 specific low-density lipoprotein-receptor sequence variants publication-title: Eur Heart J contributor: fullname: Kastelein – volume: 132 start-page: 2167 year: 2015 end-page: 2192 ident: bib13 article-title: The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association publication-title: Circulation contributor: fullname: Wierzbicki – volume: 5 start-page: S38 year: 2011 end-page: S45 ident: bib8 article-title: Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia publication-title: J Clin Lipidol contributor: fullname: Moriarty – volume: 65 start-page: 2638 year: 2015 end-page: 2651 ident: bib21 article-title: Are PCSK9 inhibitors the next breakthrough in the cardiovascular Field? publication-title: J Am Coll Cardiol contributor: fullname: Sabatine – volume: 34 start-page: 3478 year: 2013 end-page: 3490 ident: bib7 article-title: Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society publication-title: Eur Heart J contributor: fullname: Tybjærg-Hansen – volume: 25 start-page: 1960 year: 2005 end-page: 1965 ident: bib17 article-title: Tendon xanthomas in familial hypercholesterolemia are associated with cardiovascular risk independently of the low-density lipoprotein receptor gene mutation publication-title: Arterioscler Thromb Vasc Biol contributor: fullname: Mata – start-page: 2863 year: 2001 end-page: 28913 ident: bib1 article-title: Familial hypercholesterolemia publication-title: The Metabolic & Molecular Bases Oh Inherited Disease contributor: fullname: Brown – volume: 4 start-page: 850 year: 2016 end-page: 861 ident: bib12 article-title: Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel publication-title: Lancet contributor: fullname: Yamashita – volume: 372 start-page: 2387 year: 2015 end-page: 2397 ident: bib15 article-title: Ezetimibe added to statin therapy after acute coronary syndromes publication-title: N Engl J Med contributor: fullname: Califf – volume: 233 start-page: 219 year: 2014 end-page: 223 ident: bib19 article-title: Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers publication-title: Atherosclerosis contributor: fullname: Hovingh – volume: 385 start-page: 331 year: 2015 end-page: 340 ident: bib20 article-title: PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial publication-title: Lancet contributor: fullname: Gaudet – volume: 25 start-page: 182 year: 2013 end-page: 193 ident: bib14 article-title: Expert consensus on the detection and clinical management of familial hypercholesterolemia publication-title: Clin Investig Arterioscler contributor: fullname: Pedragosa – volume: 3 start-page: e001236 year: 2014 ident: bib5 article-title: Mortality among patients with familial hypercholesterolemia: a registry-based study in Norway. 1992-2010 publication-title: J Am Heart Assoc contributor: fullname: Retterstøl – volume: 29 start-page: 2625 year: 2008 end-page: 2633 ident: bib4 article-title: Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study publication-title: Eur Heart J contributor: fullname: Humphries – volume: 33 start-page: 2325 year: 2012 ident: 10.1016/j.amjcard.2016.11.025_bib6 article-title: Cardiovascular risk in relation to functionality of sequence variants in the gene coding for the low-density lipoprotein receptor: a study among 29,365 individuals tested for 64 specific low-density lipoprotein-receptor sequence variants publication-title: Eur Heart J doi: 10.1093/eurheartj/ehs038 contributor: fullname: Huijgen – volume: 92 start-page: 290 year: 1995 ident: 10.1016/j.amjcard.2016.11.025_bib16 article-title: Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation publication-title: Circulation doi: 10.1161/01.CIR.92.3.290 contributor: fullname: Ferrieres – volume: 142 start-page: 105 year: 1999 ident: 10.1016/j.amjcard.2016.11.025_bib18 article-title: Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management publication-title: Atherosclerosis doi: 10.1016/S0021-9150(98)00200-7 – volume: 49 start-page: 476 year: 1974 ident: 10.1016/j.amjcard.2016.11.025_bib3 article-title: Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia publication-title: Circulation doi: 10.1161/01.CIR.49.3.476 contributor: fullname: Stone – volume: 372 start-page: 2387 year: 2015 ident: 10.1016/j.amjcard.2016.11.025_bib15 article-title: Ezetimibe added to statin therapy after acute coronary syndromes publication-title: N Engl J Med doi: 10.1056/NEJMoa1410489 contributor: fullname: Cannon – volume: 252 start-page: 207 year: 2016 ident: 10.1016/j.amjcard.2016.11.025_bib10 publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2016.05.037 contributor: fullname: Piepoli – volume: 63 start-page: 2889 year: 2014 ident: 10.1016/j.amjcard.2016.11.025_bib11 article-title: 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2013.11.002 contributor: fullname: Stone – volume: 385 start-page: 331 year: 2015 ident: 10.1016/j.amjcard.2016.11.025_bib20 article-title: PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(14)61399-4 contributor: fullname: Raal – volume: 1 start-page: 445 year: 1992 ident: 10.1016/j.amjcard.2016.11.025_bib2 article-title: Molecular genetics of the LDL receptor gene in familial hypercholesterolemia publication-title: Hum Mutat doi: 10.1002/humu.1380010602 contributor: fullname: Hobbs – volume: 233 start-page: 219 year: 2014 ident: 10.1016/j.amjcard.2016.11.025_bib19 article-title: Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2013.12.020 contributor: fullname: Besseling – volume: 29 start-page: 2625 year: 2008 ident: 10.1016/j.amjcard.2016.11.025_bib4 article-title: Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study publication-title: Eur Heart J doi: 10.1093/eurheartj/ehn422 contributor: fullname: Neil – volume: 25 start-page: 182 year: 2013 ident: 10.1016/j.amjcard.2016.11.025_bib14 article-title: Expert consensus on the detection and clinical management of familial hypercholesterolemia publication-title: Clin Investig Arterioscler doi: 10.1016/j.arteri.2013.07.005 contributor: fullname: Masana – start-page: 2863 year: 2001 ident: 10.1016/j.amjcard.2016.11.025_bib1 article-title: Familial hypercholesterolemia contributor: fullname: Goldstein – volume: 132 start-page: 2167 year: 2015 ident: 10.1016/j.amjcard.2016.11.025_bib13 article-title: The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association publication-title: Circulation doi: 10.1161/CIR.0000000000000297 contributor: fullname: Gidding – volume: 4 start-page: 850 year: 2016 ident: 10.1016/j.amjcard.2016.11.025_bib12 article-title: Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel publication-title: Lancet contributor: fullname: Santos – volume: 3 start-page: e001236 year: 2014 ident: 10.1016/j.amjcard.2016.11.025_bib5 article-title: Mortality among patients with familial hypercholesterolemia: a registry-based study in Norway. 1992-2010 publication-title: J Am Heart Assoc doi: 10.1161/JAHA.114.001236 contributor: fullname: Mundal – volume: 5 start-page: S38 issue: 3 Suppl year: 2011 ident: 10.1016/j.amjcard.2016.11.025_bib8 article-title: Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia publication-title: J Clin Lipidol doi: 10.1016/j.jacl.2011.04.001 contributor: fullname: Ito – volume: 9 start-page: 129 year: 2015 ident: 10.1016/j.amjcard.2016.11.025_bib9 article-title: National lipid association recommendations for patient-centered management of dyslipidemia: part 1—full report publication-title: J Clin Lipidol doi: 10.1016/j.jacl.2015.02.003 contributor: fullname: Jacobson – volume: 65 start-page: 2638 year: 2015 ident: 10.1016/j.amjcard.2016.11.025_bib21 article-title: Are PCSK9 inhibitors the next breakthrough in the cardiovascular Field? publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2015.05.001 contributor: fullname: Giugliano – volume: 34 start-page: 3478 year: 2013 ident: 10.1016/j.amjcard.2016.11.025_bib7 article-title: Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society publication-title: Eur Heart J doi: 10.1093/eurheartj/eht273 contributor: fullname: Nordestgaard – volume: 25 start-page: 1960 year: 2005 ident: 10.1016/j.amjcard.2016.11.025_bib17 article-title: Tendon xanthomas in familial hypercholesterolemia are associated with cardiovascular risk independently of the low-density lipoprotein receptor gene mutation publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/01.ATV.0000177811.14176.2b contributor: fullname: Civeira |
SSID | ssj0001156 |
Score | 2.3515196 |
Snippet | Abstract Familial hypercholesterolemia (FH) is characterized by high low-density lipoprotein (LDL) cholesterol with co-dominant transmission and high risk of... Familial hypercholesterolemia (FH) is characterized by high low-density lipoprotein (LDL) cholesterol with co-dominant transmission and high risk of... |
SourceID | proquest crossref pubmed elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 742 |
SubjectTerms | Acute coronary syndromes Adult Age Arteriosclerosis Body mass index Cardiovascular Cardiovascular disease Cardiovascular Diseases - epidemiology Cholesterol Cholesterol, LDL - blood Diabetes Family medical history Female Gender Heart attacks Heterozygote Humans Hyperlipoproteinemia Type II - blood Hyperlipoproteinemia Type II - classification Hyperlipoproteinemia Type II - epidemiology Hyperlipoproteinemia Type II - genetics Hypertension Lipids Logistic Models Low density lipoprotein Male Middle Aged Multivariate Analysis Muscular Diseases - epidemiology Population Prevalence Risk Assessment Severity of Illness Index Statins Tendons Triglycerides Variables Xanthomatosis - epidemiology |
Title | Value of the Definition of Severe Familial Hypercholesterolemia for Stratification of Heterozygous Patients |
URI | https://www.clinicalkey.es/playcontent/1-s2.0-S000291491631894X https://dx.doi.org/10.1016/j.amjcard.2016.11.025 https://www.ncbi.nlm.nih.gov/pubmed/28081939 https://www.proquest.com/docview/1869947650 |
Volume | 119 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELe6ISFeEN90DJQH3pBLvhM_bm1RJdRpWsuEeLFc14aWLUHJ-rD-9dzZ-RpbxYfES9pYduLc_eL87nw-E_KWySQQiQ6oFkzSUImIskguaCRVEC00xjehH3IyS04-p6NxOO716t1W27L_qmkoA13jytm_0HZzUSiA_6BzOILW4fhHej8XF5tm5n-k9Cpb1aRwpuBplN3rAh3lE7BBCxz-TLYE-LlcCRN2aFLWYgxRwycnGDWTb6-_YsTsqc3FWnaJ7bxdoZJ101FIE-_add2f2rn5Qm3pUFyIb3lhtjp6N4PHtkx2ZJ3lsvH-mBZeBvja0okqsuq88n6f5aVpN22Cl3EnJlN0gjWPj4pVVcG6kJp6U9B9To9huF-aoIbzFU5h1L3oOkTgI9tEhHUGeebZTKi3vhDWWbEeiMs1SgCD--IB5nG1669vZuQeDz96tPQHLp3hVfGiwF-9lNmo0l8ydXu89LnLb1XdI_d8GAZxFP4SnTU8Abh4XBtnWL1dX_b-zu7tYk67LCPDkOaPyMPKtHGOLCYfk57KnpD70yp44yn5bqDp5NoBaDotNLHEQtOpoencBU0HoOnchCY27ULTqaH5jHz6MJ4PJ7Ta64PKMPWuKBB5FUZLppny_KUWKpUgHj9MtJB-qt0gYXIB1FPEsfQjHfo6SCLtgwHhyjiIF8Fzsp_lmXpJHBFKDaw8dBMmgKJ5Qi2kC7TUE8CV06Xuk0EtR_7DpnThdazjmleC5yh4MI85CL5PklravF6vDF9YVVZvU8l3ab5P0qZlxWgtU-UAx9_d9LDWK2_vk8aMhQlYVX3ywuq6eQQf99BhATv4596-Ig_a9-mQ7F8VG_Wa7JXLzRuD3J-KSNIa |
link.rule.ids | 315,782,786,27933,27934 |
linkProvider | Elsevier |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Value+of+the+Definition+of+Severe+Familial+Hypercholesterolemia+for+Stratification+of+Heterozygous+Patients&rft.jtitle=The+American+journal+of+cardiology&rft.au=P%C3%A9rez-Calahorra%2C+Sofia%2C+RD%2C+MSc&rft.au=S%C3%A1nchez-Hern%C3%A1ndez%2C+Rosa%2C+MD&rft.au=Plana%2C+N%C3%BAria%2C+MD%2C+PhD&rft.au=Marco-Benedi%2C+Victoria%2C+RD&rft.date=2017-03-01&rft.issn=0002-9149&rft_id=info:doi/10.1016%2Fj.amjcard.2016.11.025&rft.externalDBID=ECK1-s2.0-S000291491631894X&rft.externalDocID=1_s2_0_S000291491631894X |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0002-9149&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0002-9149&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0002-9149&client=summon |